We hypothesize that added neurometabolite measurements can contribute to the interpretation of the ketamine phMRI response.
ID
Bron
Verkorte titel
Aandoening
NA
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Change in levels of GABA, glutamate, and lactate in PFC; phMRI signal in PFC.
Achtergrond van het onderzoek
Pharmacological magnetic resonance imaging (phMRI), which measures the blood
flow response to drug-induced neuronal activation, is a promising technique to non-invasively
assess the brain’s response to psychotropic medication. However, phMRI measures are blood flow
based and therefore often contaminated by (systemic) cardiovascular effects frequently induced
by psychotropic medication. Magnetic resonance spectroscopy has been suggested as a technique
to more directly assess drug-induced neuronal activity and therefore allow a more complete
characterization of the brain response to psychotropic medication. We hypothesise that
concurrent measurements of the hemodynamic response and glutamate/GABA levels (with MRS)
during drug administration will provide the much-needed information to interpret the underlying
neuronal contribution to the phMRI signal. The aim of the proposed study is to provide evidence
for this hypothesis.
Doel van het onderzoek
We hypothesize that added neurometabolite measurements can contribute to the interpretation of the ketamine phMRI response.
Onderzoeksopzet
screening and 3 visits, at least 1 week apart
Onderzoeksproduct en/of interventie
Subjects will receive intravenous 0.11 mg/kg S-ketamine, 0.22 mg/kg S-ketamine or placebo during a phMRI/phMRS scan on different test sessions in
randomized order.
Algemeen / deelnemers
Wetenschappers
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
● Healthy volunteers between 18 and 55 years old;
● BMI between 18.5 and 25;
● Male or female;
● If female: using oral contraceptives and not in hormone-free week during scanning
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
● (History of) psychiatric treatment, for which prescription medication is used;
● First-degree relative with (history of) schizophrenia or major depression;
● (History) of neurological disorders (including stroke, convulsion, epilepsy) as well as concussion
with loss of consciousness
● Contraindications for S-ketamine (e.g. allergy for S-ketamine, or one of the inactive ingredients
of this product, high BP (RRsystolic > 180 mmHg or diastolic >100 mmHg), use of xantiderivatives
or methylergometrine); use of substances that interact with S-ketamine (e.g. grapefruit juice, antifungal medication)
● Contraindications for 7T MRI (e.g. claustrophobia, osteosynthetic material, pacemaker, artificial
cardiac valves);
● (History of) drug (opiate, LSD, (meth)amphetamine, cocaine, solvents, cannabis, or barbiturate)
or alcohol dependence;
● Used psychotropic medication, or recreational drugs over a period of 1 week prior to each test
session;
● Used alcohol within the last 24 hours prior to each test session.
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL8994 |
| CCMO | NL74447.018.20 |
| OMON | NL-OMON49551 |